Daljeet Singh Kohli - Head of Research at IndiaNivesh Securities is of the view that one may prefer Aurobindo Pharma.
first published: Apr 10, 2015 12:36 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

